FDA: Nitrosamine Impurity Identified in Commonly Used Acid Suppressant
NDMA was one of several nitrosamine impurities implicated in the massive recall of angiotensin II receptor blockers (ARBs) since last year.
Gastrointestinal Cancers News
GASTROINTESTINAL CANCER ADVISOR
Gastrointestinal Cancers News
Physical Activity, Overall Survival Not Linked in Metastatic CRC
Nine or more MET hours per week tied to lower risk for grade ≥3 treatment-related adverse events.
Patients, Caregivers Share High Level of Agreement in Assessments of Colorectal Cancer Care
Survey results show level of concordance between patients with CRC and their caregivers when rating care quality. The survey also measured whether clinical or demographic factors influenced the agreement between patient-caregiver pairs.
Risk of Cancer in Individuals With Lynch Syndrome Can Vary With Age, Gender, and MMR Gene Alteration
According to this prospective study, the lifetime risk of cancer in men with a pathogenic germline MSH6 alteration is relatively low.
Statins Linked to Lower Risk of Liver Cancer in Patients With Hepatitis B/C
Lipophilic statins were linked to a lower risk of hepatocellular carcinoma and death in a cohort of patients with chronic hepatitis B/C.
DAAs Cut Deaths in Those Treated for HCV-Related Liver Cancer
Findings seen for patients receiving direct-acting antivirals with complete response to liver cancer treatment.
Aspirin May Improve Liver Function After Embolization of HCC
Study suggests aspirin is hepatoprotective, improves survival by reducing liver inflammation.
Liquid Biopsy for Detecting MSI-High Status Found Concordant With Tissue-Based Testing
The new findings may extend the availability of MSI detection to all patients regardless of it they have tissue available for testing.
Younger CRC Patients More Likely to Present With Abdominal Pain
Young colorectal cancer patients more often present via emergency; have lowest percentage early-stage cancer.
Small Intestinal GISTs May Have Worse Clinical Features and Outcomes
Compared with patients who had gastric gastrointestinal stromal tumors (GISTs), patients with small intestinal GISTs had worse survival and clinical features.
Keytruda Plus Lenvima Combo Gets Breakthrough Status for Hepatocellular Carcinoma
The Breakthrough Therapy designation was based on updated interim results from the multicenter, open-label, phase 1b KEYNOTE-524/Study 116 trial.
T2DM Increases Gastric Cancer Risk After H. Pylori Eradication
Targeted screening should be considered in high-risk patients following H. pylori eradication therapy.
Proportion of CRC Diagnoses Increased in Adults Younger Than 50
Younger adults presenting with colorectal cancer present with more advanced disease than older adults.
Rates of Anal Cancer Precursors High in Women Living With HIV
Authors call for new screening strategies for anal cancer prevention in women living with HIV.
Biosimilars Mvasi, Kanjinti Now Available in the US
Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan.
The Utility of Endoscopic Techniques in the Diagnosis of Gastric Lymphoma
A case report suggests that endoscopic techniques may have utility in the diagnosis of the gastric involvement that can occur in follicular lymphoma.
Comparing Long-Course Chemoradiation With Short-Course Radiation Therapy in Rectal Cancer
Early results from the Polish II study showed a significant improvement in OS for preoperative short-course RT/chemotherapy compared with long-term chemo-RT.
Age Does Not Impact Survival After Transthoracic Esophagectomy, Study Finds
Age was not a significant prognostic factor for long-term survival after transthoracic esophagectomy among patients with thoracic esophageal cancer.
Poor Oral Health Not Linked to Gastrointestinal Cancer Risk
In site-specific analyses, significant correlation seen for poor oral health with hepatocellular carcinoma.
Biosimilar Kanjinti Gets FDA Approval for Breast, Gastric Cancer
Kanjinti, a HER2/neu receptor antagonist, is indicated for adjuvant treatment of HER2-overexpressing node positive or node negative.
Want to read more?
Please login or register first to view this content.
Next post in Gastrointestinal Cancers
